Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.61−0.06 (-0.19%)
Close on Nov 13, 2026Market cap $371.53MP/E –Yield –
Surrozen ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Surrozen's ebitda for the twelve months ending Jun 30, 2026 was -$44.13M. For fiscal 2025 it was -$41.56M. The highest annual figure on record is -$24.10M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$41.56M | – |
| FY2024 | Dec 31, 2024 | -$24.10M | – |
| FY2023 | Dec 31, 2023 | -$43.87M | – |
| FY2022 | Dec 31, 2022 | -$42.38M | – |
| FY2021 | Dec 31, 2021 | -$52.33M | – |
| FY2020 | Dec 31, 2020 | -$30.87M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.39M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.59M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.82M | -787.7% |
| Q2 FY2025 | Jun 30, 2025 | -$8.88M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.27M | – |
| Q3 FY2024 | Sep 30, 2024 | $1.57M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.60M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.18M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.37M | – |
See a number that looks wrong?